Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00431951 · ClinicalTrials.gov registry record · Phase 1

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by SIGA Technologies.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT00431951 is a Phase 1 study of Healthy that has completed, run by SIGA Technologies. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00431951, a Phase 1 study of Healthy, has completed, sponsored by SIGA Technologies.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.

Conditions Studied

Healthy

Interventions

  • DRUG Placebo
  • DRUG ST-246

Study Locations (1)

Florida

  • Orlando Clinical Research - Orlando

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2007-02
Est. Completion 2008-02
Phase Phase 1

Sponsor

SIGA Technologies

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00431951

The ClinicalTrials.gov registry entry for NCT00431951 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is SIGA Technologies, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00431951 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00431951 about?

NCT00431951 is a clinical study titled "Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers". The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.

What is the current status of trial NCT00431951?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-02. Estimated completion is 2008-02.

What conditions does trial NCT00431951 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00431951?

The interventions under investigation include: Placebo (DRUG), ST-246 (DRUG).

Who is sponsoring clinical trial NCT00431951?

This trial is sponsored by SIGA Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00431951 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.